Transperitoneal Enucleation of a Kidney Transplant Allograft Renal Cell Carcinoma

Exp Clin Transplant. 2018 Oct;16(5):614-616. doi: 10.6002/ect.2016.0037. Epub 2016 Nov 18.

Abstract

Development of malignancy after solid-organ trans?lant is a well-known long-term complication of immunosuppressive therapy. Thus far, there are no specific oncologic recommendations regarding management of de novo tumors in transplanted kidneys. Here, we present the case of a 63-year-old male patient who developed a de novo renal cell carcinoma 6 years after the transplant procedure. The patient underwent nephron-sparing surgery with transperitoneal enucleation of the tumor. We discuss the decision-making process and the operative challenges that we faced. We conclude that this technique should be considered as a therapeutic strategy for selected patients so that transplant nephrectomy can be avoided.

Publication types

  • Case Reports

MeSH terms

  • Allografts
  • Carcinoma, Renal Cell / chemically induced
  • Carcinoma, Renal Cell / immunology
  • Carcinoma, Renal Cell / pathology
  • Carcinoma, Renal Cell / surgery*
  • Clinical Decision-Making
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / surgery*
  • Kidney Neoplasms / chemically induced
  • Kidney Neoplasms / immunology
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / surgery*
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Organ Sparing Treatments*
  • Risk Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Immunosuppressive Agents